Remote Monitoring Now Available in Veeva SiteVault Free
Veeva Systems pushed forward on its remote monitoring capabilities in its Veeva SiteVault Free in response to the COVID-19 crisis. Those capabilities for source document review and verification, usually performed on-site, are contained in its free eRegulatory application. This allows study monitors to access, review, and collaborate on content online. Sites can centralize monitoring and communication with sponsors and CROs that is compliant with 21 CFR Part 11 and HIPAA requirements.
According to a survey conducted by Clinical Research IO, 63% of sites reported they have prohibited on-site monitoring by pharma sponsors and their agents. “Remote monitoring supports the immediate need for sites and study monitors to continue working together while onsite visits have largely stopped,” said Bree Burks, vice president of site strategy at Veeva and a former clinical research director. “Veeva SiteVault Free gives sites access to remote monitoring capabilities, at no cost, so they can keep running studies and treating patients.”
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
